Vaxart, Inc. Debt Conversion, Converted Instrument, Amount
Vaxart, Inc. (VXRT) reported Debt Conversion, Converted Instrument, Amount of $35.58 million for the 12-month period ending 2018-12-31, per its 10-K filed 2021-02-25.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2021-02-25
- Vaxart, Inc. debt conversion, converted instrument, amount for the quarter ending 2018-12-31 was $0.00.
- Vaxart, Inc. debt conversion, converted instrument, amount for the quarter ending 2018-09-30 was $0.00.
- Vaxart, Inc. debt conversion, converted instrument, amount for the quarter ending 2018-06-30 was $0.00.
- Vaxart, Inc. debt conversion, converted instrument, amount for the quarter ending 2018-03-31 was $35.58M.
- Vaxart, Inc. debt conversion, converted instrument, amount for fiscal 2018 was $35.58M.
| Period end | Debt Conversion, Converted Instrument, Amount | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 3 month as first filed | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $0.00 derived: sum of 2 quarters · filed 2021-02-25 | $0.00 derived: sum of 3 quarters · filed 2021-02-25 | $35.58M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $0.00 derived: sum of 2 quarters · filed 2019-11-12 | $35.58M 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $35.58M 10-Q · filed 2019-08-08 | ||||
| 2018-03-31 | $35.58M 10-Q · filed 2019-05-09 | $250.00K 10-Q · filed 2018-05-15 | ||||
| 2018-02-13 | $14.20M 10-K · filed 2019-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |